Fig. 2
From: Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Algorithm for the management of hepatic enzyme elevations in the INPULSIS® trials. *Defined as increase in hepatic transaminases (AST or ALT) to ≥3 x ULN, and i) total bilirubin >1.5 ULN or ii) INR >1.5 or iii) appearance of fatigue, nausea, vomiting, right upper abdominal quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%). In the INPULSIS® trials, routine clinical laboratory testing was undertaken at screening and weeks 2, 4, 6, 12, 18, 24, 30, 36, 44 and 52